Expression of E-cadherin in primary endometrial carcinomas: clinicopathological and immunohistochemical analysis of 30 cases

Introduction: Decreased expression of E-cadherin has been associated with poorly differentiated endometrial carcinomas and poorer outcomes. Aim: The purpose of this study was to examine the distribution of E-cadherin immunohistochemical expression in specimens from primary endometrial carcinomas and its relation to classical clinicopathological prognostic factors. Materials and Methods: Surgically-resected tissues of 30 patients with primary endometrial carcinomas were studied. Histological type and grade, depth of myometrial invasion, lymph-vascular space invasion, fallopian tube or ovarian invasion, and the presence of tumoral necrosis were evaluated. Immunohistochemical examination was performed on deparaffinized four-µm-thick sections. Results: The mean age of patients was 65 years (± 11.41). The 63.54% of carcinomas were moderately/poorly differentiated. No statistical correlation was found between the score or intensity of E-cadherin immunohistochemical staining (strong or moderate positive expression) and the clinicopathological factors tested. Conclusions: The association of E-cadherin immunoreactivity with the standard clinicopathological factors seemed to be contradictory. The classical clinicopathological factors remain the most important prognostic parameters.

E-cadherin; Carcinoma; Endometrial; Endometrioid; Immunohistochemistry; Pathology.

[1] Yalta T., Atay L., Atalay F., Caydere M., Gonultas M., Ustun H.: “E-cadherin expression in endometrial malignancies: comparison between endometrioid and non-endometrioid carcinomas”. J. Int. Med. Res., 2009, 37, 163.

[2] Ascaño J.J., Frierson H. Jr., Moskaluk C.A., Harper J.C., Roviello F., Jackson C.E. et al.: “Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer”. Mod. Pathol., 2001, 14, 942.

[3] Holcomb K., Delatorre R., Pedemonte B., McLeod C., Anderson L., Chambers J.: “E-cadherin expression in endometrioid, papillary serous and clear cell carcinoma of the endometrium”. Obstet. Gynecol., 2002, 100, 1290.

[4] Liu Fu-Shing: “Molecular carcinogenesis of endometrial cancer”. Taiwanese J. Obstet. Gynecol., 2007, 46, 26.

[5] Sakuragi N., Nishiya M., Ikeda K., Ohkouch T., Furth E.E., Hareyama H. et al.: “Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion”. Gynecol. Oncol., 1994, 53, 183.

[6] Ohashi M., Kusumi T., Sato F., Kudo Y., Jin H., Akasaka H. et al.: “Expression of syndecan-1 and E-cadherin is inversely correlated with poor patient’s prognosis and recurrent status of extrahepatic bile duct carcinoma”. Biomed. Res., 2009, 30, 79.

[7] Scholten A.N. Aliredjo R., Creutzberg C.L., Smit V.T.: “Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favourable prognostic factor in endometrial carcinoma”. Int. J. Gynecol. Cancer, 2006, 16, 1379.

[8] Mell L., Meyer J., Tretiakova M., Khramtsov A., Gong C., Yamada D.S. et al.: “Prognostic significance of E-cadherin protein expression in pathological Stage I-III endometrial cancer”. Clin. Cancer Res., 2004, 10, 5546.

[9] Horner M.J., Ries L.A.G., Krapcho M., Neyman N., Aminou R., Howlader N., et al. (eds). “SEER Cancer Statistics Review 1975- 2006, National Cancer Institute”. Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.

[10] Morrow C.P., Bundy B.N., Kurman R.J., Creasman W.T., Heller P., Homesley H.D., Graham J.E.: “Relationship between surgicalpathological risk factors and outcome in clinical Stage I and II carcinoma of the endometrium: a Gynecology Oncology Group study”. Gynecol. Oncol., 1991, 40, 55.

[11] Kadar N., Homesley H.D., Malfetano J.H.: “Prognostic factors in surgical Stage III andv IV carcinoma of the endometrium”. Obstet. Gynecol., 1994, 84, 983.

[12] Zhou Y.N., Xu C.P., Han B., Li M., Qiao L., Fang D.C., Yang J.M.: “Expression of E-cadherin and β-catenin in gastric carcinoma and its correlation with clinicopathological features and patient survival”. World J. Gastroenterol., 2002, 8, 987.

[13] Laza˘r D., Ta˘ban S., Ardeleanu C., Dema A., Sporea I., Cornianu M. et al.: “The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients’ survival”. Rom. J. Morphol. Embryol., 2008, 49, 459.

[14] Joo Y.E., Park C.S., Kim H.S., Choi S.K., Rew J.S., Kim S.J.: “Prognostic significance of E-cadherin/catenin complex expression in gastric cancer”. J. Korean Med. Sci., 2000, 15, 655.

[15] Schmalhofer O., Brabletz S., Brabletz T.: “E-cadherin, β-catenin, and ZEB1 in malignant progression”. Cancer Metastasis. Rev., 2009, 28, 151.

[16] Jawhari A., Farthing M., Pignatelli M.: “The importance of E-cadherin-catenin complex in the maintenance of intestinal epithelial homeostasis: more than intercellular glue”. Gut, 1997, 41, 581.

[17] Bansal N., Yendluri V., Wenham R.M.: “The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies”. Cancer Control., 2009, 16, 8.

[18] Ashida K., Terada T., Kitamura Y., Kaibara N.: “Expression of Ecadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study”. Hepatology, 1998, 27, 974.

[19] Perl A.K., Wilgenbus P., Dahl U., Semb H., Christofori G.: “A causal role for E-cadherin in the transition from adenoma to carcinoma”. Nature, 1998, 392, 190.

[20] Stemmer V., de Craene B., Berx G., Behrens J.: “Snail promotes Wnt target gene expression and interacts with beta-catenin”. Oncogene, 2008, 27, 5075.

[21] Peinado H., Portillo F., Cano A.: “Transcriptional regulation of cadherins during development and carcinogenesis”. Int. J. Dev. Biol., 2004, 48, 365.

[22] Shioiri M, Shida T, Koda K, Oda K, Seike K, Nishimura M, Takano S, Miyazaki M.: “Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients”. Br. J. Cancer, 2006, 94, 1816.

[23] Singh M., Spoelstra N.S., Jean A., Howe E., Torkko K.C., Clark H.R. et al.: “ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease”. Mod. Pathol., 2008, 21, 912.

[24] Blechschmidt K., Kremmer E., Hollweck R., Mylonas I., Höfler H., Kremer M., Becker K.F.: “The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas”. Diagn. Mol. Pathol., 2007, 16, 222.